Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Stratus Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Interius BioTherapeutics is a biotechnology company that delivers genetic medicines for patients.
nChroma Bio is a cutting-edge biotechnology business that is developing targeted in vivo delivery systems as well as best-in-class cargo.
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Axonis Therapeutics is a neuro-focused biotechnology company that focuses on the development of novel neuromedicines.
Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.
Triveni Bio is a a biotech company that develops functional antibodies targeting immunological and inflammatory disorders.
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
GC Therapeutics uses synthetic biology to program patient-derived stem cells into various cell types in an efficient and scalable manner.
GondolaBio researches, develops and manufactures pharmaceutical products.
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics.
Navigantis empowers physicians to deliver uncompromised neurovascular care by creating a new frontier in surgical robotics.
Adona Medical is a technology-based company that designs and develops heart failure management systems to improve heart care.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Cormorant Asset Management has invested in 209 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 13 different industry categories.
Among tracked funding rounds, GondolaBio received $300.0M in a Series Unknown round. Cormorant Asset Management's total known invested capital is $23.5B.
Cormorant Asset Management's average investment size is $137.2M across its portfolio of 209 companies.
Recent Cormorant Asset Management portfolio additions include Stratus Therapeutics, Aligos Therapeutics, GH Research, ADARx Pharmaceuticals, Umoja Biopharma. These companies were founded in 2020 or later.